Growth Investing

What I Learned from a Stock That’s Up 1,300%

anobermueller
February 1, 2013

Years ago, my dad and I were driving across his farm in his vintage Land Rover, which looks almost exactly like the one John Wayne used in the movie Hatari! The heavy-duty off-road tires were having a hard slog through the mud. Dad had cut across a recently plowed field… Read More

Apple’s Fall Spells Opportunity for this Tech Stock

SA Analysts
January 31, 2013

The most epic and motivational U.S. corporate success story may have just ended. Not only is Apple’s (Nasdaq: AAPL) share price in the process of being decimated, its fall from grace is likely to adversely affect its major suppliers.   But as you’ll see later in this article, one of Apple’s major suppliers has been able to dodge the bullet.  Before I get to the stock, here’s why Apple’s demise has opened this incredible buying opportunity… After launching successful product after successful product the world embraced, the stock… Read More

The most epic and motivational U.S. corporate success story may have just ended. Not only is Apple’s (Nasdaq: AAPL) share price in the process of being decimated, its fall from grace is likely to adversely affect its major suppliers.   But as you’ll see later in this article, one of Apple’s major suppliers has been able to dodge the bullet.  Before I get to the stock, here’s why Apple’s demise has opened this incredible buying opportunity… After launching successful product after successful product the world embraced, the stock shot from under $100 at the start of 2009 to $700 in August 2012.  Take a closer look… Now, the rug under investors has been pulled out. The stock has plunged all the way down to the current mid $400s. In fact, with a $413.89 billion market cap, the company has just lost its title as the world’s most valuable company to No. 2 , giving the title back to oil giant Exxon (NYSE: XOM), which boasts a market cap of $416.50 billion.  And it’s… Read More

Analyst Moves: CMP, XEL

David Goodboy
January 29, 2013

Imagine having the opportunity to invest into companies that are “guaranteed” by one of the world’s wealthiest men — Warren Buffett. Most investors would jump at the chance to know they are on the same side as successful investors like him.  Does this seem… Read More

This Small-Cap Biotech Could be Your Ticket to 91% Profits

Melvin Pasternak
January 29, 2013

Biotech stocks have a history of volatile moves, but the swings in this issue could make the calmest trader seasick. Between April 2009 and April 2010, biotech stock Dendreon (Nasdaq: DNDN) surged nearly 2,000%, from a low near $2.60, to a peak near $54. By July 2011, as management cut sales estimates of its flagship product, the stock had given up 80% of its value and fell to a low near $10.40. There was a countertrend rally to the mid-teens,… Read More

Biotech stocks have a history of volatile moves, but the swings in this issue could make the calmest trader seasick. Between April 2009 and April 2010, biotech stock Dendreon (Nasdaq: DNDN) surged nearly 2,000%, from a low near $2.60, to a peak near $54. By July 2011, as management cut sales estimates of its flagship product, the stock had given up 80% of its value and fell to a low near $10.40. There was a countertrend rally to the mid-teens, but after falling to the mid-$3 range, shares can now be picked up in the low $6 range.#-ad_banner-# Here’s what makes me excited now about the stock technically. It has broken a major downtrend line going back to mid-2011. In December, Dendreon cut through resistance just above $5 like a knife through butter. True, there is some resistance in the $7.80 area, but if this barrier can be exceeded, then the stock could move quickly to between $10 and $12. The shares are volatile, but in this… Read More